The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Comparative and Clinical Medicine
Volume 12 - 2025 |
doi: 10.3389/fvets.2025.1485568
Comparative Analysis of Anthelmintic Treatments: Impact on Liver Biomarkers and Clinical Recovery in Sheep with Fasciolosis
Provisionally accepted- 1 University of Gondar, Gondar, Ethiopia
- 2 department of veterinary clinical medicine college of veterinary medicine and animal medicine, Gondar, Ethiopia
- 3 Department of Veterinary Pharmacy, College of Veterinary Medicine and Animal Science, University of Gondar, Gondar, Amhara Region, Ethiopia
- 4 Department od Pathobiology, College of Veterinary Medicine and Animal Science, University of Gondar, Gondar, Amhara Region, Ethiopia
Liver fluke infections (fasciolosis) in sheep in Ethiopia result in significant economic losses, recently estimated at around $3,700 (185,232 ETH Birr) per year. Despite the widely use of Triclabendazole (TCBZ), Tetraclozan (TETRA), and Albendazole (ALBE) for treating fasciolosis, their effectiveness remains a significant concern. This study aimed to compare the efficacy of TCBZ, TETRA, and ALBE in treating ovine fasciolosis, with a focus on their effects on both the parasitic infection and associated biochemical parameters. Given the substantial economic burden of liver fluke in Ethiopia, identifying the most effective treatment options is essential to reducing both the health impact on livestock and the economic losses to farmers.A field trial was conducted from May to November 2023 on 45 naturally infected sheep, divided into three groups: Group I received TCBZ, Group II TETRA, and Group III ALBE, with TCBZ as the positive control. Fecal and serum samples were collected on days 0, 7, 14, and 21 posttreatment. A fecal egg count reduction test (FECRT) and biochemical analysis were performed.In our study, TCBZ was the most effective anthelmintic (97.8%), followed by TETRA (96.6%) and ALBE (84%). Biochemical parameters, particularly liver enzymes (AST, ALT, ALP, GGT) and protein levels, showed significant improvement across all groups over 21 days (P < 0.05), with enzyme levels normalizing by day 21 and protein levels by days 14-21. Albendazole significantly (p<0.05) outperformed Tetraclozan and Triclabendazole in both biochemical parameters and eggs per gram count (EPG), with no significant difference between Tetraclozan and Triclabendazole (P > 0.05). Albendazole proved most effective for liver recovery and normalization of biochemical markers over the treatment period (p=0.00). Among 15 Fasciolainfected animals, baseline signs included diarrhea (53%), pale mucous membranes (100%), bottle jaw (60%), and depression (80%). Post-Tetraclozan treatment, all symptoms reduced significantly over 21 days (p<0.05). In the Albendazole group, symptoms decreased progressively, with diarrhea, pale mucous membranes, bottle jaw, and depression notably reduced by days 7, 14, and 21. In conclusion, TCBZ and TETRA were highly effective against ovine fasciolosis, with TETRA recommended if TCBZ is unavailable. Biochemical parameters are key biomarkers for liver damage and selecting effective anthelmintic drugs.
Keywords: Anthelmintics, Biochemical parameters, clinical recovery, effectiveness, fasciolosis, Sheep, West Dembiya
Received: 24 Aug 2024; Accepted: 27 Jan 2025.
Copyright: © 2025 Degefaw, Mebratu, Dagnachew and Fenta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Melkie Dagnaw Fenta, University of Gondar, Gondar, Ethiopia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.